MBL Wealth LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN

MBL Wealth LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,107 shares of the biopharmaceutical company’s stock, valued at approximately $839,000.

Several other institutional investors have also added to or reduced their stakes in REGN. Western Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at about $26,000. Armstrong Advisory Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 28 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $29,000. Trust Co. of Vermont purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of REGN opened at $805.02 on Friday. The firm’s 50-day moving average price is $791.86 and its 200-day moving average price is $723.16. The firm has a market capitalization of $82.88 billion, a price-to-earnings ratio of 19.90, a PEG ratio of 1.38 and a beta of 0.16. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $575.93 and a 1-year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the previous year, the company earned $12.81 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research analyst reports. The Goldman Sachs Group boosted their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a report on Friday, July 31st. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Evercore increased their price objective on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective on the stock in a research report on Thursday, October 1st. Finally, BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $846.28.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider Andrew Murphy sold 4,147 shares of the company’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock worth $6,506,845 over the last quarter. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.